Next, we analyzed the cell line RCM1, a rectal adenocarcinoma cell line with KRAS-G12V mutation without HLA-A*11:01, to determine whether any oncogenic KRAS-carrying neoantigens would be identified from different HLA allotypes. The gene discussed is KRAS; the disease is rectum adenocarcinoma.